Study Comparing R-mabHD and a Combination of ABVD in Hodgkin's Disease

Status unconfirmed · Phase 2

Conditions studied: Hodgkin's Disease

In brief

120 subjects with Hodgkin's disease will be randomly divided into two groups: Group I receiving R-mabHD and Group II receiving a combination of Adriamycin,Bleomycin,Vinblastine and Dacarbazine. R-mabHD will be given once a week for eight weeks in a row. The ABVD combination will be given once every other week for 12 treatments. The hypothesis is that intervention with R-mabHD will lead to a quicker remission of Hodgkin's disease than the intervention with a combination of ABVD.

Key facts

Study ID
NCT00797472
Run by
American Scitech International
People needed
120
Starts
2011-07-01
Expected to finish
2014-04-01
Last updated by the study team
2011-07-20

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.